Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Hemophilia a

Hemophilia a — NIH Grants & Funding

Active and recent NIH-funded research on Hemophilia a. Data from NIH RePORTER, last 36 months.

MONDO:0010602

NIH-funded research on Hemophilia a

active grants

institutions

researchers

new in last 12 mo.

$87.7M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(15)

Basic ScienceR01Active

Targeting Regulatory T cells for Factor VIII Tolerance

Batsuli, Glaivy·STANFORD UNIVERSITY·STANFORD, CA

$758,254 (FY2026)

Hemophilia a — NIH Grants & Funding

Basic Science(15)

Targeting Regulatory T cells for Factor VIII Tolerance

Proteolytic Regulation of Factor VIII Before and After Activation

Defining the Innate Immune Cell Profile of Factor VIII Immunity

Alloimmune responses to hemophilia therapeutics

Structural and Biochemical Studies of Blood Coagulation Factor VIII to Overcome the Immune Response

Cell surface localization of FVIII mimetic therapy

Unraveling the immune response to factor VIII

Molecular and cellular mechanisms of the FVIII immune response

Center for the Investigation of Factor VIII Inhibitors and Glycosylation

An integrated computational and experimental approach to understanding the hemostatic response during treatment of bleeding

Translational(9)

cGMP Manufacture Of FVIII-Expressing Placental Cells For Hemophilia A

A New Lipid Nanoparticle Technology Enabling Long-Acting mRNA Therapy

Developing hemophilia A therapeutics by targeting translational and posttranslational regulation of FVIII

Vascular networks genetically engineered for protein drug delivery

Defining Initiating Factors Responsible for the Development of FVIII Inhibitors

Bispecific antibody to target FVIII-specific B cells

Mechanistic insights into factor VIII inhibitor formation and eradication

Defining immune pathways involved in the formation of antibodies against factor VIII

Therapeutic Applications of Factor VIIIa Inactivation in Hemophilia A

Clinical(6)

A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity

A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity

Clinical trial of AAV8-mediated FVIII gene transfer for hemophilia A

In Vivo Regulation of Factor IXa by Protein S in Hemophilia and Systemic Hypercoagulability

Testing and Implementation of the Patient-Reported Outcomes Measurement Information System Measures of Pain Intensity, Interference, and Behavior in Routine Clinical Care of Persons with Hemophilia.

Understanding of a neurophenotype in hemophilia A

Epi / Nat. History(6)

NHLBI MAINTENANCE OF CANINE MODELS OF HUMAN BLEEDING DISORDERS

The role of LDL in hemostasis

Omic Approaches to Factor VIII Inhibitor Development in Hemophilia Patients of Mexican Descent

Ultrashort Echo Time Magnetic Resonance Imaging of Hemophilic Arthropathy

NHLBI MAINTENANCE OF CANINE MODELS OF HUMAN BLEEDING DISORDERS

Abnormal Bleeding Risk in Female Hemophilia A Carriers

Gene/Cell Therapy(14)

Toward Safer Gene Therapy for Hemophilia A

A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies

Endothelial cell targeting of factor VIII for hemophilia A

Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy

Gene Editing for Hemophilia A Treatment Using Lipid Nanoparticles

Enhancing immune regulation in gene therapy for hemophilia

Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A

Platelet-derived FVIII Gene Therapy of Hemophilia A

Immunocytokine therapy for immune modulation in hemophilia

Full Gene Replacement for Hemophilia A Enabled by the StitchR Technology

Biomarker / Dx(2)

Genetic Regulation of Factor VIII Inhibitor Development

Examining Anti-Factor VIII IgM in Propagation of the Immune Response to Factor VIII in Hemophilia A

Medical Device(1)

TABA Supplement for Hemophilia Point-of-Care Device

Other(3)

Targeted, adaptive and time-variant strategies for bleed prevention across the lifespan for persons with hemophilia A

Development of a universal gene therapy for hemophilia A or B with or without inhibitors

Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A